Compare Ascendis Pharma A/S (ASND) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs NRG Energy Inc — how do they compare? Ascendis Pharma A/S trades at $263.72 (market cap $17.74B), while NRG Energy Inc trades at $138.63 (market cap $29.63B). The key difference: NRG Energy Inc is the larger of the two by market cap, and NRG Energy Inc pays a 1.35% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NRG | |
|---|---|---|
Market Cap | $17.74B | $29.63B |
Sector | Health | Utilities |
52-Week High | $277.18 | $184.03 |
52-Week Low | $163.32 | $120.65 |
Enterprise Value | $18.11B | $53.46B |
Dividend Yield | — | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
NRG Energy trades at $140.42, down 0.04% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong analyst support with 64% buy ratings, but faces high valuation with a P/E of 154.31 and modest net income margin of 0.74%. Recent earnings beat expectations in Q3 and Q4 2025, but missed in Q1 2026, with Q2 2026 results pending. Cash flow from operations was $1.91 billion in 2025, though debt levels have risen significantly.
Outlook is mixed: robust revenue growth and strategic initiatives like the smart home segment offer upside, but elevated debt and margin pressures pose risks. The stock's performance hinges on upcoming Q2 earnings and execution on EBITDA guidance of $5.325–$5.825 billion for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
